Anandappa Gayathri, Chau Ian
Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK; Department of Medicine, Royal Marsden Hospital, London, UK.
Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK; Department of Medicine, Royal Marsden Hospital, London, UK.
Hematol Oncol Clin North Am. 2017 Jun;31(3):529-544. doi: 10.1016/j.hoc.2017.02.001. Epub 2017 Mar 22.
With further understanding of the biology of gastric and gastroesophageal adenocarcinomas, strides are being made to find effective treatments through novel trial designs. This article focuses on the ongoing trials of drugs targeting specific hallmarks of gastric and gastroesophageal cancers, including oncogene addiction proliferative pathways (fibroblast growth factor receptor 2 amplified tumors), stem cell inhibition, apoptotic induction through claudin inhibitors, and matrix metalloproteinase inhibition. In developing novel therapeutics in treatment of patients with gastroesophageal adenocarcinomas, parallel research efforts to refine target population and biomarkers are crucial, and targeting the tumor genomics and microenvironment may be key in improving overall survival.
随着对胃腺癌和胃食管腺癌生物学特性的进一步了解，人们正通过新颖的试验设计努力寻找有效的治疗方法。本文重点关注针对胃和胃食管癌特定特征的药物正在进行的试验，这些特征包括癌基因成瘾增殖途径（成纤维细胞生长因子受体2扩增肿瘤）、干细胞抑制、通过claudin抑制剂诱导凋亡以及基质金属蛋白酶抑制。在开发治疗胃食管腺癌患者的新型疗法时，完善目标人群和生物标志物的平行研究工作至关重要，而针对肿瘤基因组学和微环境可能是提高总体生存率的关键。
